408507-86-8

Basic information

• Product Name: 5-amino-2-hexylphenol
• Synonyms: 5-amino-2-hexylphenol
• CAS NO: 408507-86-8
• Molecular Weight: 193.289
• Mol File: 408507-86-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-amino-2-hexylphenol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-2-hexylphenol(408507-86-8)
• EPA Substance Registry System: 5-amino-2-hexylphenol(408507-86-8)

Safety Data

• Hazardous Substances Data: 408507-86-8(Hazardous Substances Data)

Upstream product

• 136-77-6 4-Hexylresorcinol 

Downstream Products

• 1252577-07-3 [3-(tert-butyldiphenylsiloxy)-4-hexylphenyl]-(6-chloro-9H-purin-2-yl)-amine 
• 1252577-09-5 (2-{2-[3-(tert-butyldiphenylsiloxy)-4-hexylphenylamino]-6-chloro-purin-9-yl}-ethoxymethyl)-phosphonic acid diethyl ester 
• 1252577-11-9 {2-[6-chloro-2-(4-hexyl-3-hydroxyphenylamino)-purin-9-yl]-ethoxymethyl}-phosphonic acid diethyl ester 
• 1077883-92-1 {2-[6-amino-2-(4-hexyl-3-hydroxy-phenylamino)-purin-9-yl]-ethoxymethyl}-phosphonic acid 
• 1252577-04-0 {2-[6-amino-2-(4-hexyl-3-hydroxyphenylamino)-purine-9-yl]-ethoxymethyl}-phosphonic acid diethyl ester 
• 1252577-05-1 3-(tert-butyldiphenylsiloxy)-4-hexylphenylamine 

Relevant articles and documents

Antitumor effects of guanosine-analog phosphonates identified by molecular modelling

Aiming to address new drug targets, molecular modelling is gaining increasing importance although the prediction capability of the in silico method is still under debate. For an improved treatment of actinic keratosis and squamous cell carcinoma, inhibitors of human DNA polymerase α (pol α) are developed by docking nucleoside phosphonate diphosphates into the active site of pol α. The most promising prodrugs OxBu and OxHex were then prepared by total synthesis and tested in the squamous cancer cell line SCC25. OxBu and OxHex proved cytotoxic and antiproliferative in the nanomolar concentration range and thus exceeded activity of aphidicolin, the relevant model compound, and 5-fluorouracil, the current standard for the therapy of actinic keratosis. Interestingly, the cytotoxicity in normal human keratinocytes with OxHex was clearly less pronounced and even not detectable with OxBu. Moreover, cytotoxicity of OxBu in particular with the colorectal carcinoma cell line HT29 even surmounted cytotoxicity in SCC25, and other tumor cell lines were influenced, too, by both agents. Taken together, OxBu and OxHex may offer a new approach to cancer therapy, given the agents are sufficiently well tolerated in vivo which is to be suspected beside their chemical structure.